Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozanolixizumab self-administration in generalized myasthenia gravis
NCT05681715Phase 3Completed
- Sponsor
- UCB
- Start
- Apr 2023
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of rozanolixizumab in myasthenia gravis (MG) (2 arms), sponsored by UCB. Primary endpoint: Percentage of Participants With Successful Self-administration of Rozanolixizumab at 18 weeks. Started Apr 2023; status: completed.
02
Drugs
rozanolixizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT05681715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05681715.